Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

MSD and EyeBio Announce Phase 2b/3 Clinical Trial of Restoret™ (MK-3000) for Diabetic Macular Oedema

Sep 4, 2024

On 4 September 2024, Merck (MSD) and EyeBio announced the initiation of the phase 2b/3 BRUNELLO trial (NCT06571045) evaluating Restoret™ (MK-3000, formerly EYE103) for the treatment of diabetic macular oedema (DME).

Restoret™ is a tri-specific antibody that acts as an agonist of the Wingless-related integration site signalling pathway and is EyeBio’s lead candidate.

MSD announced its acquisition of EyeBio for US$3 billion in May 2024.  The acquisition was completed in July 2024.